Imdelltra monitoring time reduced for first two doses

What this means

Imdelltra (tarlatamab-dlle) is Amgen's bispecific T-cell engager that directs the immune system to attack small-cell lung cancer cells expressing DLL3, approved for adults with extensive-stage SCLC that has progressed after platinum-based chemotherapy. Because tarlatamab can trigger cytokine release syndrome (CRS), the original label required patients to be monitored for 22 to 24 hours in a healthcare setting after each of the first two infusions. On Sept 14 the FDA approved a label update that reduces this required monitoring period to 6 to 8 hours from the start of each of those first two infusions, with a next-day follow-up assessment including vital signs. The reduction is intended to make Imdelltra easier to administer in community oncology settings and reduce the amount of time patients spend in the clinic during initial treatment.